0001127602-16-045126.txt : 20160304
0001127602-16-045126.hdr.sgml : 20160304
20160304180754
ACCESSION NUMBER: 0001127602-16-045126
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160302
FILED AS OF DATE: 20160304
DATE AS OF CHANGE: 20160304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bradway Robert A
CENTRAL INDEX KEY: 0001396482
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 161486439
MAIL ADDRESS:
STREET 1: AMGEN INC.
STREET 2: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2016-03-02
0000318154
AMGEN INC
AMGN
0001396482
Bradway Robert A
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320-1799
1
1
Chairman, CEO and President
Common Stock
2016-03-02
4
A
0
113175
0
A
383102
D
Common Stock
2016-03-02
4
M
0
20000
50.44
A
403102
D
Common Stock
2016-03-02
4
S
0
20000
146.4783
D
383102
D
Common Stock
2016-03-02
4
M
0
64000
50.44
A
447102
D
Common Stock
2016-03-02
4
F
0
43799
148.39
D
403303
D
Nqso (Right to Buy)
50.44
2016-03-02
4
M
0
20000
0
D
2010-04-28
2016-04-28
Common Stock
20000
64000
D
Nqso (Right to Buy)
50.44
2016-03-02
4
M
0
64000
0
D
2010-04-28
2016-04-28
Common Stock
64000
0
D
The price reported is an average price. The prices ranged from $146.41 to $146.72 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
Open market exercise of 20,000 stock options expiring April 28, 2016 wherein a portion of the cash received as a result of the exercise of these options was used to cover the option exercise price and the remaining balance was remitted in full by the Company to the appropriate California and federal taxing authorities to cover the reporting person's tax liability arising from the reported transactions.
Non-market exercise of 64,000 stock options expiring April 28, 2016 wherein 43,799 shares issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and statutory tax withholding, with the remaining shares delivered to the reporting person.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 7,119 RSUs which vest on 4/27/2016; 6,356 RSUs which vest on 1/28/2017; 10,139 RSUs which vest in two installments of 4,994 and 5,145 on 1/31/2017 and 1/31/2018, respectively; and 13,398 shares which vest in two equal installments of 4,421 on 1/30/2017 and 1/30/2018 and one installment of 4,556 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 1,555 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
/s/ Andrea A. Robinson, Attorney-in-Fact for Mr. Bradway
2016-03-04